脑脊液可溶性CD27水平作为临床孤立综合征预后生物标志物
这项前瞻性研究纳入77例临床孤立综合征(CIS)患者,检测脑脊液可溶性CD27(sCD27)水平,发现CIS患者sCD27高于对照组。平均随访54.8个月,50.6%患者诊断为多发性硬化(MS)。校正影像和脑脊液指标后,sCD27每升高100 U/mL,MS诊断风险比为2.4;高sCD27患者年复发率是低水平者的5.5倍。
要点
- CIS患者脑脊液sCD27水平显著高于对照组。
- sCD27每升高100 U/mL,MS诊断风险增加(HR 2.4)。
- 高sCD27者年复发率较低者高5.5倍。
核心结论
- 脑脊液sCD27水平与CIS患者后续MS诊断及高复发率相关,是潜在的临床决策标志物。
研究设计与样本
- 前瞻性研究,纳入2002年3月至2015年5月间77例CIS患者,在首次症状6个月内行腰穿和MRI。
主要发现
- CIS患者脑脊液sCD27几何均值31.3 U/mL(95%CI 24.0-40.9),高于对照组4.67 U/mL(95%CI 2.9-7.5),P<.001。
- 平均随访54.8个月,39/77例(50.6%)诊断为MS。
- 校正MRI和脑脊液指标后,sCD27每升高100 U/mL,MS诊断风险比2.4(95%CI 1.27-4.53,P=.007)。
- 高sCD27(中位数>31.4 U/mL)MS患者年复发率0.33,低水平者0.06,P=.02。
关键数值与推荐
- sCD27每升高100 U/mL对应MS诊断风险比2.4(95%CI 1.27-4.53,P=.007)。
- 高sCD27阈值(中位数>31.4 U/mL)者年复发率0.33 vs 0.06(P=.02)。
临床怎么用
- 对CIS患者检测脑脊液sCD27可能有助于识别高MS诊断风险和高复发风险者,辅助治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is a growing number of therapies that could be administered after the first symptom of central nervous system demyelination. These drugs can delay multiple sclerosis (MS) diagnosis and slow down future disability. However, treatment of patients with benign course may not be needed; therefore, there is a need for biomarkers to predict long-term prognosis in patients with clinically isolated syndrome (CIS). OBJECTIVE: To investigate whether the T-cell activation marker soluble CD27 (sCD27) measured in cerebrospinal fluid of patients at time of a first attack is associated with a subsequent diagnosis of MS and a higher relapse rate. DESIGN, SETTING, AND PARTICIPANTS: This prospective study included 77 patients with CIS between March 2002 and May 2015 in a tertiary referral center for multiple sclerosis, in collaboration with several regional hospitals. Patients with CIS underwent a lumbar puncture and magnetic resonance imaging scan within 6 months after first onset of symptoms. MAIN OUTCOMES AND MEASURES: Soluble CD27 levels were determined in cerebrospinal fluid using a commercially available enzyme-linked immunosorbent assay. Cox regression analyses was used to calculate univariate and multivariate hazard ratios for MS diagnosis. Association between sCD27 levels and relapse rate was assessed using a negative binomial regression model. RESULTS: Among 77 patients with CIS, 50 were female (79.5%), and mean (SD) age was 32.7 (7.4) years. Mean (SD) age in the control individuals was 33.4 (9.5) years, and 20 were female (66.7%).Patients with CIS had higher cerebrospinal fluid sCD27 levels than control individuals (geometric mean, 31.3 U/mL; 95% CI, 24.0-40.9 vs mean, 4.67 U/mL; 95% CI, 2.9-7.5; P < .001). During a mean (SD) follow-up of 54.8 (35.1) months, 39 of 77 patients (50.6%) were diagnosed as having MS. In a model adjusted for magnetic resonance imaging and cerebrospinal fluid measurements, sCD27 levels were associated with a diagnosis of MS (hazard ratio, 2.4 per 100 U/mL increase in sCD27 levels; 95% CI, 1.27-4.53; P = .007). Additionally, patients with MS with high sCD27 levels (median, >31.4 U/mL) at the time of CIS had a 5.5 times higher annualized relapse rate than patients with low sCD27 levels (annualized relapse rate, 0.06 vs 0.33; P = .02). CONCLUSIONS AND RELEVANCE: Soluble CD27 in cerebrospinal fluid of patients with CIS was associated with MS diagnosis and a high relapse rate. Therefore, sCD27 is an activation molecule directly related to the immunopathology of the disease and is a potential clinical marker to help in treatment decisions after a first attack of suspected MS.
引用
- van der Vuurst de Vries RM, Mescheriakova JY, Runia TF, et al. Soluble CD27 Levels in Cerebrospinal Fluid as a Prognostic Biomarker in Clinically Isolated Syndrome. JAMA Neurol. 2017. PMID: 28055081. doi:10.1001/jamaneurol.2016.4997
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。